An infusion reaction to cetuximab.
Elizabeth S. Waxman
View on PubMed
Abstract & Figures
Sorry, we couldn't extract an abstract for this paper.
Figures and Tables
Sorry, we couldn't extract any figures or tables for this paper.
Sorry, we couldn't extract any citations for this paper.
Sorry, we couldn't extract any references for this paper.
Loading similar papers…
Slides referencing similar topics
Cetuximab single agent in platinum- refractory patients
Sandrine Faivre • Oct 19, 2017
Treatment of patients with KRAS and NRAS wild type advanced colorectal cancer with 5-fluorouracil (5-FU) or 5-FU plus an Epidermal Growth Factor Receptor inhibitor (cetuximab) based on a Comprehensive Geriatric Assessment
Marc Peeters • Nov 07, 2017
Phase 1b Study of the Selective BRAF V600 Inhibitor Encorafenib (LGX818) Combined With Cetuximab With or Without the α-specific PI3K Inhibitor Alpelisib (BYL719) in Patients With Advanced BRAF-mutant Colorectal Cancer
Jan H.M. Schellens + 16 • Oct 27, 2017